long-acting semaglutide / Nanexa AB - LARVOL DELTA

Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell (TradingView) - "Nanexa has now completed a pharmacokinetic study in rats using several PharmaShell semaglutide formulations. These new data, in combination with human modelling, indicate that semaglutide can potentially be administered once every three months (quarterly) while maintaining a controlled and therapeutically relevant plasma concentration...Lower initial plasma concentration peaks are considered key to minimizing gastrointestinal side effects such as nausea — a major reason for treatment discontinuation in GLP‑1 therapies."

Preclinical • Obesity • Type 2 Diabetes Mellitus

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation (Business News This Week) - "Recent preclinical studies demonstrate an extraordinary pharmacokinetic (PK) profile, indicating a very low ratio between the maximum and minimum plasma concentration over the dosing interval following once-monthly subcutaneous administration. The plasma concentration is significantly more stable than that typically achieved with weekly administration of the marketed product Wegovy (semaglutide)....The preclinical results show clear dose-linearity, and significantly improved bioavailability compared with Nanexa’s earlier liraglutide formulations. Improved tolerability is strongly linked to improved adherence, which is a key issue associated with GLP-1 therapies."

PK/PD data • Preclinical • Obesity